Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure

Series
External life support
Status
Ongoing
Date
Number of report
034

Ask the expert

(we accept only company emails)

The report presents a summary of reimbursement situation for Extra-corporeal membrane oxygenation (ECMO) for pulmonary and cardiac failure.

Both veno-venous and veno-arterial ECMO is considered.

The use of ECMO is considered in the following situations:

  • Acute respiratory distress syndrome (VV-ECMO)
  • Deterioration of chronic advanced heart failure (VA-ECMO)
  • Post-cardiotomy cardiogenic shock (VA-ECMO)
  • Post-myocardial infarction cardiogenic shock (VA-ECMO)

The only reimbursement within public / statutory health insurance systems is considered.

Report includes essential information about reimbursement and national funding, including:

  • Brief overview of reimbursement system for medical devices
  • Procedure coding for technology
  • Diagnosis coding
  • Payment mechanism for technology
  • Reimbursement tariffs for technology
  • Restrictions in indications or scenarios for use of technology
  • Policy considerations by payers and policy-makers about technology

Reimbursement information is provided for the following geographies:

  • Austria
  • Belgium
  • Denmark
  • England (UK)
  • France
  • Germany
  • Italy
  • Netherlands
  • Norway
  • Sweden
  • Switzerland

Manufacturers of extra-corporeal membrane oxygenation devices for pulmonary and cardiac failure report include:

  • Abbott Vascular (CentriMag, PediVAS)
  • Fresenius / XENIOS AG (Medos device)
  • Getinge (CARDIOHELP System, Rotaflow Centrifugal Pump System, PLS System)
  • Hemovent GmbH (Portable ECMO system)
  • Medtronic (BPX-80, BP-50)
  • Terumo (CAPIOX SP Centrifugal Pump)

Table of content is not available at the moment.

There are no relevant news at the moment
(we accept only company emails)